Is there an optimal sequential order to androgen receptor axis therapeutics?

Area of Science:

• Oncology
• Pharmacology
• Urology

Background:

• The prostate cancer therapeutic landscape has evolved significantly with novel hormonal agents.
• Abiraterone acetate and second-generation antiandrogens (enzalutamide, darolutamide, apalutamide) show enhanced efficacy over older treatments.
• These newer agents effectively target the androgen receptor signaling pathway and overcome resistance mechanisms.

Purpose of the Study:

• To provide a comprehensive review of landmark clinical trials for abiraterone acetate and second-generation antiandrogens.
• To examine real-world off-label prescribing practices for these advanced prostate cancer therapies.
• To offer insights into optimal sequencing strategies for antiandrogen therapy based on current evidence.

Main Methods:

• Review of pivotal clinical trials leading to FDA approval of abiraterone and second-generation antiandrogens.
• Analysis of real-world data on prescribing patterns and off-label use.
• Synthesis of current data to guide antiandrogen sequencing.

Main Results:

• Abiraterone acetate and second-generation antiandrogens demonstrate superior efficacy in prostate cancer treatment compared to first-generation agents.
• These agents are effective in overcoming resistance mechanisms associated with earlier therapies.
• Evidence supports specific sequencing strategies for maximizing therapeutic benefit in different prostate cancer settings.

Conclusions:

• The expanded hormonal therapeutic options necessitate careful consideration of patient-specific factors for optimal medication selection.
• Understanding landmark trials and real-world data is crucial for effective clinical decision-making.
• Optimal sequencing of abiraterone acetate and second-generation antiandrogens is key to improving outcomes in advanced prostate cancer.